Elizabeth Masson-Hurlburt
Corporate Officer/Principal at CORMEDIX INC.
Net worth: 235 610 $ as of 2024-04-29
Elizabeth Masson-Hurlburt active positions
| Companies | Position | Start | End |
|---|---|---|---|
| CORMEDIX INC. | Corporate Officer/Principal | - | - |
| Chief Tech/Sci/R&D Officer | 2018-02-28 | - |
Career history of Elizabeth Masson-Hurlburt
Former positions of Elizabeth Masson-Hurlburt
| Companies | Position | Start | End |
|---|---|---|---|
| NEUROBO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2016-07-31 | 2018-02-28 |
Training of Elizabeth Masson-Hurlburt
| Bay Path College | Undergraduate Degree |
Statistics
International
| United States | 4 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| CORMEDIX INC. | Health Technology |
| Private companies | 1 |
|---|---|
Gemphire Therapeutics, Inc.
 Gemphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI. | Health Technology |
